Glaucoma and goniodysgenesis DNA testing for Border Collies
Border Collies are renowned for their intelligence, agility, and working prowess, making them popular among both working dog enthusiasts and active pet owners alike. However, like many breeds, they are at risk of certain hereditary health issues, one of which is glaucoma and goniodysgenesis (GGD), a serious eye condition that can lead to blindness.
Responsible breeders in the UK now commonly use DNA health testing for glaucoma and goniodysgenesis to identify affected and carrier dogs. This helps prevent passing on this painful condition and promotes the overall health of the breed.
Understanding glaucoma and goniodysgenesis in Border Collies
Goniodysgenesis is an abnormal development of the anterior chamber drainage angle in the eye, disrupting normal fluid outflow and causing increased intraocular pressure. Elevated pressure damages the optic nerve, leading to glaucoma, which is frequently painful and can cause irreversible blindness.
Symptoms to watch for in affected dogs include watery or runny eyes, sensitivity to light, eye discomfort or pain, abnormal eye movements, and dilated pupils. Early detection is crucial for managing the disease progression.
Research in 2025 highlights a key genetic variant on the OLFML3 gene associated with severe goniodysgenesis and early-onset glaucoma in Border Collies. This mutation follows an autosomal recessive inheritance pattern, meaning a dog must inherit two copies of the mutated gene—one from each parent—to be at significant risk.
How glaucoma and goniodysgenesis are inherited by Border Collies
The OLFML3 gene mutation passes through generations according to autosomal recessive heredity. The possible genetic status outcomes in breeding pairs are:
- Two affected parents will produce an affected litter.
- Two clear parents will produce clear pups free from the mutation.
- Two carrier parents can produce pups that are affected, carriers, or clear according to Mendelian probabilities (25% affected, 50% carriers, 25% clear).
- Clear and carrier parents will produce half clear and half carrier pups.
- Clear and affected parents will produce carrier-only litters.
- Carrier and affected parents will produce half affected and half carrier pups.
Awareness of these inheritance patterns empowers breeders to make informed decisions to reduce disease incidence by using DNA testing before mating.
DNA testing procedures and best breeding practices in the UK 2025
To identify the genetic status of breeding dogs, DNA samples are collected through a simple veterinary procedure, often a cheek swab or blood test, and sent to an approved UK laboratory for testing the OLFML3 mutation.
The test results classify dogs into three categories: clear (no mutation), carrier (one copy), or affected (two copies). Breeders use this information alongside thorough veterinary eye exams to select suitable mating pairs that minimise producing affected puppies.
Best practices include:
- Never mating two carriers or two affected dogs together.
- Pairing a clear dog with either a clear or a carrier dog preferentially.
- Continuing regular veterinary eye screenings, as environmental and other genetic factors can influence disease development even in genetically clear dogs.
- Sharing DNA test results transparently within the breeding community.
These strategies collectively support the health and longevity of Border Collies and reduce the prevalence of GGD in the breed over time.
Conclusion
Glaucoma and goniodysgenesis DNA testing for Border Collies using the OLFML3 gene mutation is an essential tool for responsible breeders in the UK in 2025. Combined with veterinary eye examinations and deliberate breeding choices, it offers a practical way to reduce this serious hereditary eye disease and improve the welfare of this beloved breed.
Prospective owners seeking Border Collie puppies should prioritise reputable breeders who conduct comprehensive health screening, including GGD DNA tests, to help ensure a healthy, happy companion for years to come.
